Foresee Pharmaceuticals announced that the company will present the clinical design of the FP-045 Phase 1/2 clinical Fanconi anemia clinical study currently being initiated, at the Fanconi Anemia.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On May 8, 2023, the Company appointed Dr.. | May 11, 2023
The rise in the incidence of ARDS stimulates the research and development of the drug, as it is likely to provide an appropriate environment for newer products to be profitable. Companies across
The rise in the incidence of ARDS stimulates the research and development of the drug, as it is likely to provide an appropriate environment for newer products.